Valuation: vTv Therapeutics Inc.

Market Cap 429M 373M 349M 319M 603M 40.91B 611M 4.08B 1.6B 20.44B 1.61B 1.58B 68.04B P/E 2026 *
-18.8x
P/E 2027 * -8.63x
Enterprise Value 429M 373M 349M 319M 603M 40.91B 611M 4.08B 1.6B 20.44B 1.61B 1.58B 68.04B EV / Sales 2026 *
16.2x
EV / Sales 2027 * -
Free-Float
61.02%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
1 week+5.91%
Current month+6.99%
1 month+0.20%
3 months+9.25%
6 months+19.26%
Current year-13.45%
1 week 31.5
Extreme 31.5
35.31
1 month 29.44
Extreme 29.44
35.78
Current year 28.75
Extreme 28.75
44
1 year 14
Extreme 14
44
3 years 7.38
Extreme 7.38
44
5 years 7.38
Extreme 7.38
86.8
10 years 7.38
Extreme 7.38
336
Manager TitleAgeSince
Chief Executive Officer 68 2022-07-31
Director of Finance/CFO 50 2025-05-18
Chief Tech/Sci/R&D Officer - 2023-11-01
Director TitleAgeSince
Director/Board Member 56 2020-11-15
Director/Board Member 48 2022-07-10
Chairman 68 2024-02-29
Date Insider Type Main position Quantity % Market Cap.
6/26/26 Free

Director

6,000 0.1523%
2/17/26 Free

Chief Financial Officer

44,969 1.1419%
2/17/26 Free

Chief Executive Officer

140,000 3.5551%
Change 5-day change 1-year change 3-year change Capi.($)
+0.64%+5.91%+136.77%+20.83% 429M
-3.25%+13.72%+52.49%+88.86% 62.92B
+2.81%+4.03%+34.60%+75.30% 54.32B
-1.07%-1.79%-18.07%-14.36% 22.91B
+33.86%+30.60%+19.14%+502.77% 28.73B
+10.83%+18.38%+52.76%+4.58% 21.65B
+8.84%+10.09%+41.44%-19.48% 17.76B
-3.37%+25.85%+213.21%+369.13% 16.47B
+6.20%+11.51%+34.94%+681.88% 15.48B
-7.94%-6.74%+38.42%+157.52% 13.12B
Average +4.75%+7.86%+60.57%+186.70% 25.38B
Weighted average by Cap. +4.82%+8.61%+46.54%+166.52%

Financials

2026 *2027 *
Net sales 26.46M 22.96M 21.5M 19.67M 37.13M 2.52B 37.62M 252M 98.72M 1.26B 99.35M 97.19M 4.19B -
Net income -23.19M -20.12M -18.84M -17.23M -32.54M -2.21B -32.96M -220M -86.5M -1.1B -87.05M -85.16M -3.67B -59.26M -51.43M -48.16M -44.05M -83.16M -5.65B -84.25M -563M -221M -2.82B -223M -218M -9.39B
Net Debt - -
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change Volume
26-08-06 US$34.61 +0.64% 139,960
26-08-05 US$34.39 +7.27% 102,676
26-08-04 US$32.06 -1.02% 63,434
26-08-03 US$32.39 +0.12% 171,175
26-07-31 US$32.35 -1.01% 136,838
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
34.61USD
Average target price
53.83USD
Spread / Average Target
+55.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTVT Stock